Kala Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Merck €1 Billion Notes Offering
Davis Polk advised the representatives of the underwriters, in connection with the offering of €1 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were…
Patheon N.V. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $719 million initial public offering by Patheon N.V. (“Patheon”). The IPO comprised…
McKesson formation of a new company with Change Healthcare Holdings
Davis Polk advised McKesson Corporation on its creation of a new health care information technology company, which will combine substantially all of Change Healthcare Holdings, Inc.’s…
Universal American Corp. $115 Million Convertible Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Universal American Corp. of an aggregate principal amount of $115 million of 4.00% convertible senior…
AbbVie Inc. Offering of $7.8 Billion Senior Notes
Davis Polk advised the representatives of the underwriters, in connection with an SEC-registered offering by AbbVie Inc. (“AbbVie”) of $7.8 billion aggregate principal amount of senior…
Ardelyx, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with an $86.2 million SEC-registered follow-on common stock offering of 8,625,000 shares of common stock for Ardelyx, Inc…
Davis Polk Advises Penumbra, Inc. on Its $138 Million Initial Public Offering
Davis Polk advised Penumbra, Inc. on its SEC-registered initial public offering of 4,600,000 shares of common stock for an aggregate price to the public of approximately $138 million,…
Seattle Genetics, Inc. $552 Million Equity Offering
Davis Polk advised the underwriters, in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,463,415 shares of common stock, which includes 1,756,097 shares of common…
Celgene $8.0 Billion Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $8.0 billion aggregate principal amount of notes. The notes were issued in…